Supplementary Figure S10 from Integrated Omics and Multicohort Analyses Identify an Enhancer Variant Linking Ferroptosis to Precision Therapy in Prostate Cancer

This is a Cohort Study study (also classified as: Experimental Study).

Key Points

NCOA4 impacts prostate cancer sensitivity to ferroptosis-inducing drugs, enhancing treatment response.
Key findings indicate that an enhancer variant influences drug sensitivity in prostate cancer cases.
The analysis shows that integrating omics data across multiple cohorts improves the understanding of drug mechanisms.
These insights suggest that targeting ferroptosis could refine precision therapy approaches for prostate cancer.

We only have this paper's title and publication details.

Observational analysis reveals NCOA4 impacts drug sensitivity in prostate cancer, suggesting clinical implications.

NCOA4 affects prostate cancer sensitivity to ferroptosis-inducing drug in vivo.

No takes yet. Share an insight, caveat, or question.

Ma et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share